Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
  • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
  • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1617—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2009—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
  • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives

Definitions

• the present invention relates to a complex formulation for oral administration comprising amlodipine camsylate and simvastatin, and a method for preparation thereof.
• Hyperlipidemia or serum lipid level elevation is related to the occurrence of cardiovascular diseases and arteriosclerosis.
• the hyperlipidemia includes hypercholesterolemia, familial dysbetalipoprotenemia, diabetic dyslipemia, nephritic dyslipemia and familial combined hyperlipidemia.
• Hypercholesterolemia a representative example of hyperlipidemia, is caused by elevated serum LDL (low-density lipoprotein)-cholesterol and total cholesterol levels, and the treatment of hypercholestrolemia by reducing the serum lipid level, especially the LDL-cholesterol level, makes it possible to lower the risk of cardiovascular disorders, which leads to delayed progression of arteriosclerosis (American diabetes association, Diabetic care, 23 (suppl.), S57- S65, 2000).
• Hypertension is accompanied by hyperlipidemia in many cases, which may cause cardiac disorders such as angina pectoris. Thus, it is very important to control hypertension together with the cholesterol level when a patent is suffering from coronary heart diseases, so that the risk or fatality arising from cardiovascular disorders can be reduced.
• Kramsch et al. have disclosed that a calcium channel blocking agent such as amlodipine, an antihypertension agent, can be administered together with a lipid-lowering agent to enhance the therapeutic effects against atherosclerosis (Kramsch et. al. , Journal of Human Hypertension, Suppl. 1, 53-59, 1995), and Lichtlen P. R. et al. have reported that an early atherosclerotic disease in human can be effectively treated by co-administering a calcium channel blocking agent (Lichtlen P. R. et al, Lancet, 335, 1109-1139, 1990; and Waters D. et al, Circulation, 82, 1940-1953, 1990).
• a calcium channel blocking agent such as amlodipine, an antihypertension agent
• statin drugs including atrovastatin are useful for treating atherosclerosis, and it has been reported that in case of administering a statin drug (pravastatin or lovastatin) together with a calcium channel blocking agent (amlodipine), atherosclerotic diseases can be better treated through synergistic effects of the two drugs (Jukema et. al., Circulation, Suppl. 1, 1-197, 1995; and Orekhov et. al., Cardiovescular Drug and Theraphy, 11, 350, 1997).
• a statin drug pravastatin or lovastatin
• amlodipine calcium channel blocking agent
• Caduet ® a commercially available atrovastatin-amlodipine besylate complex formulation wherein astrovastatin is a HMG-CoA reductase inhibitor and amlodipine besylate is a therapeutic for hypertension
• astrovastatin is a HMG-CoA reductase inhibitor
• amlodipine besylate is a therapeutic for hypertension
• the present inventors have found that a complex formulation for oral administration comprising amlodipine camsylate, which has superior photostability than amlodipine besylate's, exhibits improved stability.
• a complex formulation comprising amlodipine camsylate and simvastatin, which are therapeutics for hypertension and hyperlipidemia, respectively, and a method for preparation thereof.
• a complex formulation for oral administration comprising amlodipine camsylate, simvastatin, and a stabilizing agent.
• Fig. 1 a schematic diagram of the inventive complex formulation comprising amlodipine camsylate and simvastatin;
• Fig. 2 a graph showing the changes in the amlodipine besylate and amlodipine camsylate contents when exposed to sunlight
• Fig. 3 the amounts of degradation products of amlodipine besylate and amlodipine camsylate when exposed to sunlight
• Fig. 4 the amounts of degradation products of amlodipine besylate and amlodipine camsylate when exposed to incandescent light;
• Fig. 5 the changes in the amlodipine content when the solid dispersions prepared in Comparative Example 1 and Examples 1 to 4 were subjected to stability tests;
• Fig. 6 the amounts of the degradation products of amlodipine generated when the solid dispersions prepared in Comparative Example 1 and Examples 1 to 4 were subjected to stability tests
• Fig. 7 the change in the amlodipine content during the stability test of the complex formulations prepared in Comparative Example 2 and Examples 5 to 7;
• Fig. 8 the amounts of the degradation products of amlodipine during the stability tests of the complex formulations prepared in Comparative Example 2 and Examples 5 to 7;
• Fig. 9 the changes in the amlodipine content during the stability tests of the complex formulations prepared in Examples 7 and Comparative example 3;
• Fig. 10 the amount of the degradation product of amlodipine during the stability tests for the complex formulations prepared in Examples 7 and Comparative example 3;
• Fig. 11 the changes in the simvastatin content during the stability tests of the complex formulations prepared in Comparative Examples 2 and 3, and Examples 5 to 7;
• Fig. 12 the changes in the amlodipine content through the comparative stability tests of the complex formulation prepared in Example 7 and a control formulation, Caduet ® ;
• Fig. 13 the amounts of the degradation products of amlodipine during the comparative stability test for the complex formulation prepared in Example 7 and a control formulation, Caduet ® .
• the complex formulation of the present invention is characterized by comprising amlodipine camsylate and simvastatin, which are therapeutics for hypertension and hyperlipidemia, respectively, as shown in Fig. 1.
• the pharmaceutically active ingredient of the complex formulation according to the present invention comprises amlodipine camsylate, which is a blocking agent for calcium channel, used for treating hypertension; and simvastatin (U.S. Patent No: 4,448,784 and 4,450,171), which is a HMG-CoA reductase inhibitor, used for treating hyperlipidemia and arteriosclerosis by lowering the lipoprotein or lipid level in blood.
• amlodipine camsylate has superior photostability than amlodipine besylate known as the most appropriate amlodipine salt so far.
• Amlodipine camsylate may be employed in an amount ranging from 0.5 to 20 % by weight, preferably from 1 to 10 % by weight based on the total weight of the complex formulation. When the amount is less than 0.5 % by weight, its therapeutic effect cannot be expected, and when more than 20 % by weight, a safety problem may arise because it exceeds the allowable daily dose.
• Simvastatin may be employed in an amount ranging from 0.5 to 50 % by weight, preferably from 1 to 40 % by weight based on the total weight of the complex formulation. When the amount is less than 0.5 % by weight, its therapeutic effect cannot be expected, and when more than 50 % by weight, a safety problem may arise because it exceeds the allowable daily dose.
• the complex formulation according to the present invention comprises a stabilizing agent which prevents the oxidation of amlodipine camsylate and simvastatin used as a pharmaceutically active ingredient.
• the stabilizing agent used in the present invention may be any one of the known stabilizing agents, and exemplary stabilizing agents include butylated hydroxy toluene (BHT), butylated hydroxy anisol (BHA), erythorbic acid, ascorbic acid, tocopherol and the like.
• BHT butylated hydroxy toluene
• BHA butylated hydroxy anisol
• stabilizing agent may be employed in an amount ranging from 0.001 to 100 % by weight, preferably 0.002 to 50 % by weight based on the weight of amlodipine camsylate.
• the sustained release formulation of the present invention may further comprise at least one of the known pharmaceutically acceptable additives such as a dispersing agent, binder, lubricating agent, sweetening agent, excipient and the like, in order to prepare a solid formulation suitable for oral administration.
• a dispersing agent such as a dispersing agent, binder, lubricating agent, sweetening agent, excipient and the like
• the pharmaceutically acceptable additive may include any one of the binder generally used in pharmacy, such as polyvinylpyrrolidone (PVP), gelatin, hydroxypropyl cellulose and Copovidone, and any one of the lubricating agent generally used in pharmacy, such as sucrose fatty acid ester, talc, light anhydrous silicic acid, zinc and magnesium salts of stearic acid and the like.
• PVP polyvinylpyrrolidone
• talc hydroxypropyl cellulose and Copovidone
• lubricating agent such as sucrose fatty acid ester, talc, light anhydrous silicic acid, zinc and magnesium salts of stearic acid and the like.
• step 2) mixing the solid dispersion obtained in step 1 with simvastatin and a pharmaceutically acceptable additive to obtain a mixture, and granulating the mixture by wet milling to obtain granules, followed by formulating the granules.
• the organic solvent may be methanol, ethanol, dichloromethane, chloroform and the like, and the solid dispersion may be prepared by a conventional method such as spray-drying, solvent evaporating, micropulverizing- wetting, melting, and freeze-drying methods.
• a solvent such as water, ethanol and dichloromethane may be employed to form a binder solution during the preparation of the granules comprising the pharmaceutically active ingredients of the complex formulation, amlodipine camsylate and simvastatin.
• the above method according to the present invention may further comprise the step of coating the obtained complex formulation with a film layer for protecting the formulation from degenerative factors such as light and moisture as well as for enhancing the patient compliance (e.g., by blocking a bitter taste).
• the outer film layer may be a light-shielding film layer, moisture-proof film layer or sugar film layer.
• the preferable film layer may comprises at least one of the known water-soluble film-forming materials such as hydroxypropylmethylcellulose
• HPMC hydroxypropylcellulose
• HPC hydroxyethylcellulose
• CAP celluloseacetatephthalate
• EC ethylcellulose
• MC methylcellulose
• Kollicoat ® BASF, Germany
• Opadry ® Colorcon, USA
• the water-soluble film layer may be employed in an amount ranging from 0.5 to 20 % by weight, preferably 1 to 10 % by weight based on the weight of the inventive complex formulation. When the amount is less than 0.5 % by weight, the film becomes unstable, and when more than 20 % by weight, it adversely affects the drug release.
• the water-soluble film layer may further comprise plasticizers such as polyethyleneglycol (PEG), glycerol triacetate and acetylated monoglyceride.
• amlodipine camsylate-simvastatin complex formulation of the present invention prepared by the above method has an improved effect of the pharmaceutically active ingredients by releasing them rapidly and has improved stability of amlodipine camsylate and simvastatin by comprising the stabilizing agent.
• the inventive complex formulation can be effectively used for preventing and treating hyperlipidemia, arteriosclerosis, hypertension, cardiovascular disease and the combined disease thereof when orally administered once per day at a single dose.
• Amlodipine camsylate, an active ingredient, and BHT (UENO Fine Chemical, USA), a stabilizing agent, were dissolved in 100 mi of a mixture of ethanol and dichloromethane (2:8, w/w) according to the amounts described in Table 1, respectviely, and each of the resulting mixture was subjected to spray- drying to obtain a solid dispersion
• Complex formulations for oral administration were prepared using the components described in Table 2.
• the solid dispersions prepared in Examples 1 to 4 and Comparative Example 1 were each mixed with simvastatin, an active ingredient for treating hyperlipidemia, microcrystalline cellulose, mannitol, dibasic calcium phosphate and sodium starch glycolate.
• a binder solution prepared by dissolving 3 mg of Povidone (BASF, Germany) in about 50 mi of purified water was added to the mixture, which was granulated by wet milling to obtain granules.
• the granules were dried and passed through a 750 //iri-sieve.
• Magnesium stearate as a lubricating agent was added to the granules and an amlodipine camsylate-simvastatin complex formulation for oral administration was prepared by a conventional tabletting method.
• a complex formulation for oral administration was prepared using the components listed in Table 3. Simvastatin, microcrystalline cellulose, mannitol, dibasic calcium phosphate and sodium starch glycolate were mixed together, and a binder solution prepared by dissolving 3 mg of Povidone (BASF, Germany) in about 50 mi of purified water was added thereto. The resulting mixture was granulated by wet milling to obtain granules. The granules were dried and passed through a 750 /an-sieve. The solid dispersion comprising amlodipine camsylate and BHT, prepared by the methods of Examples 1 to 4, was added to the sieved granules. Then, magnesium stearate, a lubricating agent, was added to the resulting mixture, and an amlodipine camsylate- simvastatin complex formulation for oral administration was prepared by a conventional tabletting method.
• Preprocessin gained from a sample for 30 amlodipine gained from a sample in min in 100 ml of mobile phase a solution of 0.02 M of acetate buffer g for samples and filtration in 200 ml of solution (pH 5.0):acetonitrile 1:1 mobile phase and filtration
• Fig. 2 shows the time-dependant degradation rate of amlodipine besylate and amlodipine camsylate by the action of sunlight
• Fig. 3 shows the amount of rate of impurity generation from amlodipine by the action of sunlight
• Fig. 4 the rate of impurity generation from amlodipine caused by incandescent light exposure.
• Test Example 1 Stability test of a solid dispersion of amlodipine camsylate- stabilizing agent
• the stability of amlodipine improves as the amount of BHT, a stabilizing agent, increases.
• Test Example 2 Stability test of a solid dispersion of amlodipine camsylate- simvastatin
• amlodipine camsylate and simvastatin are subjected to granulation together as described in
• Example 7 for the decreased chance for amlodipine camsylate to contact magnesium stearate.
• Fig. 11 shows the change in the simvastatin content, showing that BHT elevates the stability of simvastatin.
• Test Example 3 Comparative stability test of a complex formulation as compared with a control formulation
• amlodipine camsylate-simvastatin complex formulation of Example 7 and the amlodipine besylate-atorvastatin complex formulation, Caduet ®

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Inorganic Chemistry (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=38218207

Family Applications (1)

Country Status (11)

Cited By (2)

Families Citing this family (8)

Citations (3)

Family Cites Families (5)

• 2005
  • 2005-12-27 KR KR1020050130531A patent/KR100742432B1/ko not_active Expired - Fee Related
• 2006
  • 2006-12-22 RU RU2008130873/15A patent/RU2008130873A/ru not_active Application Discontinuation
  • 2006-12-22 AU AU2006330199A patent/AU2006330199A1/en not_active Abandoned
  • 2006-12-22 WO PCT/KR2006/005658 patent/WO2007075009A1/en not_active Ceased
  • 2006-12-22 CA CA002634639A patent/CA2634639A1/en not_active Abandoned
  • 2006-12-22 BR BRPI0620790-1A patent/BRPI0620790A2/pt not_active IP Right Cessation
  • 2006-12-22 EP EP06835362A patent/EP1978956A4/en not_active Withdrawn
  • 2006-12-22 JP JP2008548399A patent/JP2009521526A/ja not_active Withdrawn
  • 2006-12-22 US US12/159,418 patent/US20090005425A1/en not_active Abandoned
  • 2006-12-22 CN CNA2006800492048A patent/CN101346140A/zh active Pending
• 2008
  • 2008-06-12 IL IL192148A patent/IL192148A0/en unknown

Patent Citations (3)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events